ImmunoGen names new vice president and chief medical officer

Dr O’Leary will lead the clinical development of ImmunoGen’s product candidates. Prior to joining ImmunoGen, Dr O’Leary was senior medical director of clinical oncology at Bayer where his responsibilities included leading the global clinical development team for a late-stage anticancer agent.

Before joining Bayer in 2006, Dr O’Leary was medical director of clinical oncology at Pfizer. Dr O’Leary has earned his medical degree from the State University of New York – Health Science Center at Brooklyn in 1990.

Daniel Junius, president and COO of ImmunoGen, said: “Jim has all of the skills to effectively lead the development of our clinical-stage compounds and provide strategic input on our earlier-stage programs. He has experience in all phases of product development – from preclinical to registration – and in clinical drug development for major international markets as well as for the US. We’re particularly pleased that Jim’s background includes experience at the FDA as well as at leading healthcare companies.”